| | | | | S-1 | | | |
| | | | | S-6 | | | |
| | | | | S-11 | | | |
| | | | | S-13 | | | |
| | | | | S-14 | | | |
| | | | | S-17 | | | |
| | | | | S-18 | | | |
| | | | | S-19 | | | |
| | | | | S-23 | | | |
| | | | | S-24 | | | |
| | | | | S-30 | | | |
| | | | | S-30 | | | |
| | | | | S-31 | | | |
| | | | | S-31 | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 10 | | | |
| | | | | 17 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 22 | | |
| | |
Fiscal year
|
| |||||||||||||||||||||||||||
| | |
2018
|
| |
2019
|
| |
2020
|
| |
1Q2020
|
| |
1Q2021
|
| |||||||||||||||
Cash flow from operations(1)
|
| | | | 291 | | | | | | 219 | | | | | | 3 | | | | | | (33) | | | | | | 22 | | |
Capital expenditures/investments
|
| | | | 128 | | | | | | 99 | | | | | | 50 | | | | | | 16 | | | | | | 8 | | |
Free cash flow (non-GAAP)
|
| | | | 163 | | | | | | 119 | | | | | | (47) | | | | | | (49) | | | | | | 13 | | |
| | |
Fiscal Year
|
| |||||||||||||||||||||||||||
| | |
2018
|
| |
2019
|
| |
2020
|
| |
1Q2020
|
| |
1Q2021
|
| |||||||||||||||
Net Income (GAAP)
|
| | | | 99 | | | | | | 127 | | | | | | (277) | | | | | | (136) | | | | | | (1) | | |
Tax expense
|
| | | | 8 | | | | | | 13 | | | | | | (103) | | | | | | (55) | | | | | | 2 | | |
Interest & other expense, net
|
| | | | 7 | | | | | | 2 | | | | | | 9 | | | | | | 2 | | | | | | 3 | | |
Depreciation & amortization expense
|
| | | | 96 | | | | | | 88 | | | | | | 91 | | | | | | 24 | | | | | | 22 | | |
Gain on investments in unconsolidated affiliates
|
| | | | 5 | | | | | | (39) | | | | | | — | | | | | | — | | | | | | — | | |
Dividends on Series A preferred stock
|
| | | | — | | | | | | — | | | | | | 13 | | | | | | — | | | | | | 5 | | |
Direct & incremental Series A preferred stock issuance costs
|
| | | | — | | | | | | — | | | | | | 10 | | | | | | — | | | | | | — | | |
EBITDA (non-GAAP)
|
| | | | 215 | | | | | | 192 | | | | | | (256) | | | | | | (166) | | | | | | 31 | | |
Impairment of assets and lease terminations
|
| | | | 18 | | | | | | 18 | | | | | | 219 | | | | | | 192 | | | | | | 1 | | |
Acquisition-related costs
|
| | | | — | | | | | | 5 | | | | | | 3 | | | | | | 1 | | | | | | — | | |
Acquisition-related contingent consideration and amortization expense
|
| | | | — | | | | | | 1 | | | | | | (4) | | | | | | (4) | | | | | | | | |
COVID-19 related costs
|
| | | | — | | | | | | — | | | | | | 23 | | | | | | 3 | | | | | | 5 | | |
Adjusted EBITDA (non-GAAP)
|
| | | | 233 | | | | | | 216 | | | | | | (15) | | | | | | 25 | | | | | | 38 | | |
| | |
As of March 30, 2021
|
| |||||||||||||||||||||
| | |
Actual
|
| |
As adjusted
|
| |
As further
adjusted |
| |
Pro forma
as further adjusted |
| ||||||||||||
| | |
(In thousands, except share and per share data)
|
| |||||||||||||||||||||
Cash and cash equivalents
|
| | | $ | 181,345 | | | | | $ | | | | | $ | | | | | $ | | | |||
Debt: | | | | | | | | | | | | | | | | | | | | | | | | | |
Revolving credit facility(1)(2)
|
| | | $ | 280,000 | | | | | $ | 280,000 | | | | | $ | 280,000 | | | | | $ | 280,000 | | |
Principal amount of % convertible senior notes due 2026 we are offering pursuant to the concurrent offering(3)
|
| | | | — | | | | | | — | | | | | | 300,000 | | | | | | 300,000 | | |
Total debt
|
| | | | 280,000 | | | | | | 280,000 | | | | | | 580,000 | | | | | | 580,000 | | |
Series A convertible preferred stock, $0.01 par value per share; 200,000 shares authorized, 200,000 shares issued and outstanding, actual, as adjusted and as further adjusted; no shares issued and outstanding, pro forma as further adjusted
|
| | | | 213,485 | | | | | | 213,485 | | | | | | 213,485 | | | | | | — | | |
Stockholders’ equity: | | | | | | | | | | | | | | | | | | | | | | | | | |
Preferred stock, $0.01 par value per share, other
than Series A convertible preferred stock; 4,800,000 shares authorized, no shares issued and outstanding, actual, as adjusted, as further adjusted and pro forma as further adjusted |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Common stock, $0.01 par value per share; 250,000,000 shares authorized; 99,508,470 shares outstanding, actual; shares outstanding, as adjusted and as further adjusted; shares outstanding, pro forma as further adjusted(4)
|
| | | | 995 | | | | | | | | | | | | | | | | | | | | |
Additional paid-in capital(3)
|
| | | | 904,045 | | | | | | | | | | | | | | | | | | | | |
Retained earnings(5)
|
| | | | 1,114,047 | | | | | | 1,114,047 | | | | | | 1,114,047 | | | | | | 1,114,047 | | |
Treasury stock, 53,101,293 shares at cost, actual, as adjusted, as further adjusted and pro forma as further adjusted
|
| | | | (1,700,700) | | | | | | (1,700,700) | | | | | | (1,700,700) | | | | | | (1,700,700) | | |
Accumulated other comprehensive loss
|
| | | | (1,873) | | | | | | (1,873) | | | | | | (1,873) | | | | | | (1,873) | | |
Total stockholders’ equity(3)(5)
|
| | | | 316,514 | | | | | | | | | | | | | | | | | | | | |
Total capitalization(3)(5)
|
| | | $ | 809,999 | | | | | $ | | | | | $ | | | | | $ | | | |
Underwriter
|
| |
Number of Shares
|
| |||
J.P. Morgan Securities LLC
|
| | | | | | |
BNP Paribas Corp.
|
| | | | | | |
BofA Securities, Inc.
|
| | | | | | |
Wells Fargo Securities, LLC
|
| | | | | | |
Total
|
| | | | | |
| | |
Paid by The Cheesecake Factory
Incorporated |
| |||||||||
| | |
No
|
| |
Full
|
| ||||||
| | |
Exercise
|
| |
exercise
|
| ||||||
Per Share
|
| | | $ | | | | | $ | | | ||
Total
|
| | | $ | | | | | $ | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 5 | | | |
| | | | | 6 | | | |
| | | | | 7 | | | |
| | | | | 8 | | | |
| | | | | 10 | | | |
| | | | | 17 | | | |
| | | | | 21 | | | |
| | | | | 22 | | | |
| | | | | 22 | | |